KemPharm announced topline results from the first of three pivotal human abuse potential trials for KemPharm’s product candidate, KP415, which is based on a prodrug of d-methylphenidate for the treatment of attention deficit/hyperactivity disorder. “The results from our first pivotal human abuse potential trial for the prodrug contained within KP415 and KP484 could not have been better,” said KemPharm CEO Travis Mickle. “The prodrug itself was not readily converted to the active d-methylphenidate when injected and as a result, produced pharmacodynamic effects that were comparable to placebo based on multiple endpoints of the study. Since lower potential abuse is one of the key elements of the potential value that KP415 and KP484 would bring to the market, we believe these data truly differentiate our prodrug from current stimulant-based ADHD products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.